The Safety of Thiopurine Treatment in Pregnant Women with Inflammatory Bowel Disease

Byong Duk Ye

doi:10.4166/kjg.2011.58.1.61

Journal List > Korean J Gastroenterol > v.58(1) > 1006903

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Ye: The Safety of Thiopurine Treatment in Pregnant Women with Inflammatory Bowel Disease

Research Update

Korean J Gastroenterol 2011;58(1):61-63.

Published online: 4 October 2011

DOI: https://doi.org/10.4166/kjg.2011.58.1.61

The Safety of Thiopurine Treatment in Pregnant Women with Inflammatory Bowel Disease

Byong Duk Ye

Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

Correspondence to: Byong Duk Ye, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea. Tel: +82-2-3010-3181, Fax: +82-2-476-0824, E-mail: bdye@amc.seoul.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME study

References

1. Githens JH, Rosenkrantz JG, Tunnock SM. Teratogenic effects of azathioprine (Imuran). J Pediatr. 1965; 66:959–961.

2. Rosenkrantz JG, Githens JH, Cox SM, Kellum DL. Azathioprine (Imuran) and pregnancy. Am J Obstet Gynecol. 1967; 97:387–394.

3. Platzek T, Bochert G. Dose-response relationship of ter-atogenicity and prenatal-toxic risk estimation of 6-mercaptopur-ine riboside in mice. Teratog Carcinog Mutagen. 1996; 16:169–181.

4. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002; 65:240–261.

5. N⊘rgård B, Pedersen L, Christensen LA, S⊘rensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol. 2007; 102:1406–1413.

6. Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thio-purines: cohort from the CESAME Study. Gut. 2011; 60:198–203.

7. van der Woude CJ, Kolacek S, Dotan I, et al. European evi-denced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis. 2010; 4:493–510.

8. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007; 56:830–837.

9. Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007; 133:1106–1112.

10. Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007; 79:696–701.

11. De Vigan C, Khoshnood B, Lhomme A, Vodovar V, Goujard J, Goffinet F. Prevalence and prenatal diagnosis of congenital malformations in the Parisian population: twenty years of surveillance by the Paris Registry of congenital malformations. J Gynecol Obstet Biol Reprod (Paris). 2005; 34:8–16.

TOOLS

Similar articles